Tag: site

GREENWICH, Conn., June 13, 2025 (GLOBE NEWSWIRE) -- Aetherium Acquisition (the “SPAC” or the “Company”), a publicly-traded special purpose acquisition company, today announced that its Special Meeting (“Meeting”), previously scheduled at 8:30 a.m. Eastern Time on June 13, 2025, has been postponed to 8:30 a.m. Eastern Time on June 27, 2025, and the redemption right deadline has been postponed to 5:00 p.m. Eastern Time on June 25, 2025.

RoboCat now accepts deposits from just $1 and offers exclusive bonuses and rewards on small deposits, making online casino gaming more accessible for everyone

Shenzhen, China, June 13, 2025 (GLOBE NEWSWIRE) -- With Father's Day approaching, it's time to give your father a truly practical and trustworthy gift. As a brand specializing in high-performance Lithium Iron Phosphate (LiFePO4) batteries, Power Queen is launching a limited time offer on highly popular battery products for this special holiday, and is also opening a site-wide promotional campaign to bring users a holiday full of sincerity. During the event period, enjoy 6% off on all battery orders (Code: FATHER6), and 8% off on orders over $1500 (No Code Needed)

NEW YORK, June 13, 2025 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of NET Power Inc. (NYSE: NPWR, NPWR.WS) between June 9, 2023 and March 7, 2025, both dates inclusive (the “Class Period”), of the important June 17, 2025 lead plaintiff deadline.

Radcred’s exclusive 2025 study reveals the safest, fastest-paying crypto casinos reshaping online gambling. See trends, data, and tips. 

Curated 5,500-Square-Foot Venue Launches June 14 Across from Chateau Marmont with Premium Brands, Gourmet Experiences, and Hollywood Design Flair

The Most Beautiful Race in the World Returns to Italian Roads 

NEW YORK, June 13, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, today announces that dosing has commenced at the prestigious Weill Cornell Medicine Multiple Sclerosis Center in New York City, in its ongoing Phase 2 clinical trial evaluating intranasal foralumab in patients with non-active Secondary Progressive Multiple Sclerosis (na-SPMS). This fifth site complements existing sites at Yale University, Johns Hopkins University, Brigham and Women's Hospital, and the University of Massachusetts.

COMMUNIQUE DE PRESSE DU 13 JUIN 2025
RELATIF A LA MISE EN ŒUVRE DU RETRAIT OBLIGATOIRE DE LA SOCIETE